Other research analysts have also issued research reports about the stock. William Blair initiated coverage on shares of Incyte in a research note on Tuesday, March 21st. They issued an outperform rating on the stock. Royal Bank of Canada reiterated a buy rating and issued a $138.00 price target on shares of Incyte in a research note on Friday, March 31st. BMO Capital Markets reiterated an outperform rating and issued a $126.00 price target on shares of Incyte in a research note on Tuesday, December 6th. Instinet initiated coverage on shares of Incyte in a research note on Wednesday, March 1st. They issued a buy rating and a $148.00 price target on the stock. Finally, Barclays PLC upped their price target on shares of Incyte from $105.00 to $135.00 and gave the company a buy rating in a research note on Thursday, January 19th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $139.40.
Shares of Incyte (NASDAQ:INCY) opened at 123.11 on Monday. Incyte has a 52-week low of $68.03 and a 52-week high of $153.15. The stock has a market cap of $23.32 billion, a P/E ratio of 227.98 and a beta of 0.78. The firm’s 50-day moving average price is $138.77 and its 200-day moving average price is $114.39.
Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.14 by $0.09. The firm earned $326 million during the quarter, compared to the consensus estimate of $324.90 million. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 earnings per share. On average, equities research analysts forecast that Incyte will post ($0.08) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Incyte’s (INCY) “Outperform” Rating Reiterated at Cowen and Company” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/04/21/incyte-co-incy-receives-outperform-rating-from-cowen-and-company-2-updated.html.
In other Incyte news, insider David W. Gryska sold 41,528 shares of the firm’s stock in a transaction on Monday, April 10th. The shares were sold at an average price of $138.00, for a total value of $5,730,864.00. Following the completion of the sale, the insider now directly owns 20,754 shares in the company, valued at $2,864,052. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven H. Stein sold 32,000 shares of the firm’s stock in a transaction on Friday, April 7th. The stock was sold at an average price of $137.88, for a total transaction of $4,412,160.00. Following the completion of the sale, the executive vice president now owns 41,648 shares of the company’s stock, valued at $5,742,426.24. The disclosure for this sale can be found here. Insiders have sold 127,571 shares of company stock valued at $18,145,772 in the last three months. 13.70% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 22 shares in the last quarter. Ngam Advisors L.P. boosted its position in shares of Incyte by 0.4% in the third quarter. Ngam Advisors L.P. now owns 11,898 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 47 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in shares of Incyte by 1.7% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 4,328 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 72 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its position in shares of Incyte by 1.0% in the third quarter. Sumitomo Mitsui Asset Management Company LTD now owns 11,567 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 114 shares in the last quarter. Finally, HighTower Advisors LLC boosted its position in shares of Incyte by 1.2% in the third quarter. HighTower Advisors LLC now owns 13,226 shares of the biopharmaceutical company’s stock worth $1,244,000 after buying an additional 159 shares in the last quarter. Institutional investors and hedge funds own 92.62% of the company’s stock.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
What are top analysts saying about Incyte Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Incyte Co. and related companies.